# metabolic dysfunction-associated steatohepatitis (MASH) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 15768
- Completion tokens: 6621
- Reasoning tokens: 1763
- Total tokens: 22389
- API requests reported: 1
- Elapsed seconds: 68.477
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1019.869
- Question handoff seconds: 1032.938
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded interpretation of transcriptomic data comparing MASH vs healthy liver. Let me analyze the input carefully.

**Statistical Input Summary:**
- 100 genes total (49 downregulated, 51 upregulated)
- All genes have FDR ≤ 0.01 (highly significant)
- Task: Disease-state differential expression (log2FC)
- Context: MASH liver tissue vs healthy controls

**Key observations from the data:**

1. **Direction split**: 51 up, 49 down - fairly balanced

2. **Strong upregulated genes (log2FC > 3)**:
- UBD (4.15) - ubiquitin D, immune/inflammatory marker
- TREM2 (4.91) - macrophage/Kupffer cell marker, strongly associated with NASH
- CXCL10 (3.46) - chemokine, T cell/NK cell recruitment
- UQCRBP1 (3.73) - mitochondrial
- DTNA (3.72) - dystrobrevin alpha
- TMEM154 (3.71) 
- TRNC (4.07) - tRNA
- CAST (4.02) - calpastatin
- HS3ST2 (3.72) - heparan sulfate sulfotransferase
- TNFRSF12A (3.27) - TWEAK receptor, proliferation/inflammation
- TP53I3 (3.26) - p53-induced gene
- DUSP8 (3.49) - dual specificity phosphatase
- MTRNR2L8 (3.25) - mitochondrially encoded
- MIR12136 (3.18)
- SNORD140 (3.06)
- TRNS1 (3.05)

3. **Strong downregulated genes (log2FC < -2.5)**:
- PCDH20 (-4.59) - protocadherin
- TIMD4 (-4.28) - phosphatidylserine receptor on Kupffer cells
- DIO3OS (-3.88)
- DIO3OS antisense
- MS4A6E (-3.52) - myeloid marker
- CR1 (-3.61) - complement receptor
- MARCO (-2.84) - macrophage scavenger receptor
- CD5L (-2.90) - macrophage scavenger receptor
- LYVE1 (-2.73) - lymphatic vessel endothelial hyaluronan receptor
- SPIC (-2.62)
- CETP (-2.49)
- CD163 (-2.52) - macrophage/hemoglobin scavenger
- CD209 (-2.43)
- VCAM1 (-2.38) - vascular cell adhesion
- MRC1 (-2.10) - mannose receptor, M2 macrophage
- SIGLEC1 (-2.12) - sialoadhesin
- FOLR2 (-2.04)
- CSF1R (-1.98) - macrophage CSF receptor
- TINAGL1 (-1.78)
- CFP (-1.86) - complement factor properdin
- MPEG1 (-1.74)
- RASL10B (-2.57)
- MAST1 (-2.73)
- LDB2 (-1.53)

**Key biological themes:**

1. **Macrophage/Kupffer cell dynamics**: 
- The downregulated genes are dominated by classical M2/anti-inflammatory macrophage markers: MARCO, CD5L, CD163, MRC1, SIGLEC1, FOLR2, CSF1R, CD209, LYVE1 (sinusoidal endothelial)
- TREM2 is strongly upregulated - this is the key marker of disease-associated macrophages (DAMs) in NASH/MASH
- TIMD4 (down) is interesting because TIM-4 mediates efferocytosis in Kupffer cells
- This suggests macrophage repolarization from M2-like to TREM2+ pro-inflammatory/steatohepatitis-associated macrophages

2. **Inflammatory/chemokine signaling**:
- CXCL10 (up) - IFN-γ-induced chemokine, T cell recruitment
- TNFRSF12A (up) - TWEAK/FN14 receptor, fibrogenic
- UBD (up) - ubiquitin D, marks inflammation
- VCAM1 (down) - actually this is interesting, usually up in inflammation

3. **Mitochondrial/metabolic dysfunction**:
- UQCRBP1 (up) - complex III assembly
- CYCS (up) - cytochrome c
- MTRNR2L8 (up) - mitochondrial RNA
- TIMM17A (up) - mitochondrial translocase
- FABP5 (up) - fatty acid binding
- CBS (down) - cystathionine beta-synthase, homocysteine/methionine
- MTHFD1L (up) - one-carbon metabolism
- GLUD1P2 (down) - glutamate dehydrogenase pseudogene
- SCLY (down) - selenocysteine lyase

4. **Cell adhesion/ECM**:
- PCDH20 (down) - protocadherin
- CDH5 (down) - VE-cadherin
- CDH23 (down) - cadherin
- TINAGL1 (down) - extracellular matrix
- P4HA1 (down) - prolyl hydroxylase, collagen biosynthesis
- FNBP1 (down) - formin binding protein

5. **Mitochondrial tRNA enrichment**:
- TRNK, TRNS1, TRNC, TRNL2, TRNY - all upregulated mitochondrial tRNAs
- This is unusual - suggests mitochondrial stress response

6. **Cell cycle/proliferation**:
- FOXM1 (up) - cell cycle transcription factor
- CAST (up) - calpastatin
- EME1 (up) - DNA repair
- AJUBA (up) - hippo signaling

7. **Transcription factors**:
- ETV5 (down) - ETS family
- TCF7L1 (down) - Wnt pathway
- FOXM1 (up) - proliferation
- TSC22D1 (up) - TGF-β stimulated

8. **Heparan sulfate**:
- HS3ST2 (up) - heparan sulfate 3-O-sulfotransferase
- NDST3 (down) - N-deacetylase/N-sulfotransferase

**Pathway enrichment context from RAG**:
- GO:0098742 Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules
- GO:0030450 Regulation Of Complement Activation, Classical Pathway
- GO:1905907 Negative Regulation Of Amyloid Fibril Formation
- KEGG: Aminoacyl-tRNA biosynthesis, Tuberculosis, Malaria

These KEGG hits (Tuberculosis, Malaria) are consistent with macrophage activation signatures - they share immune/granuloma biology with MASH.

**Network evidence**:
- C3-CFP-CR1: complement cascade
- CD163-MRC1-SIGLEC1: macrophage markers
- CSF1R-TREM2: macrophage signaling
- CTNNB1-CDH5-FOXM1-TCF7L1: Wnt/catenin/cadherin axis
- HS2ST1-HS3ST2-NDST3: heparan sulfate biosynthesis
- HSPA5-CD5L-MANF: ER stress/UPR related

**Literature context**:
- PMID 39497821 - efferocytosis-related biomarkers for MASH diagnosis (relevant!)
- PMID 42089112 - miR-26a-5p and MASH progression
- PMID 29503738 - CX3CR1 in disease
- PMID 39699377 - PDE2A as biomarker (PDE2A is downregulated here)
- PMID 38323273 - MTHFD1L (upregulated here)

**Now let me construct the response.** I need to:
1. Overall biological interpretation
2. Core biological programs (≤5)
3. Key genes and interaction modules (≤10)
4. Validation priorities (≤5)
5. Evidence grounding
6. Limitations and alternatives (≤5)

Let me structure this carefully and make sure I:
- Cite real PMIDs from the literature record
- Distinguish evidence types
- Don't conflate association with causation
- Note that no external validation cohort is available
- Stay within the limits

Let me write this carefully and concisely.</think>

# Multidimensional Interpretation: MASH vs Healthy Liver Transcriptome

## 1. Overall biological interpretation

The 100-gene signature separates MASH from healthy liver along three integrated axes: **(i) a macrophage-composition/repolarization shift**, **(ii) an inflammatory/fibrogenic signaling program**, and **(iii) a coordinated metabolic–stress program centered on mitochondrial tRNAs, one-carbon flux, and altered cell–cell adhesion**. The downregulated half is unusually enriched for resident Kupffer-cell/M2-like macrophage markers (MARCO, CD5L, CD163, MRC1, SIGLEC1, FOLR2, CSF1R, LYVE1, TIMD4, CD209) — together these are the classical "tissue-resident macrophage" gene set. Their loss in bulk tissue is consistent with either depletion, loss-of-identity, or numerical dilution by an *expanding* macrophage subset, because the strongest single upregulated gene in the whole list is **TREM2 (log2FC +4.91)**, the canonical marker of monocyte-derived, lipid-associated macrophages (LAMs) that accumulate in steatohepatitis. Layered onto this is a chemokine/injury module (CXCL10, TNFRSF12A/FN14, UBD), a mitochondrial tRNA burst (TRNK, TRNS1, TRNC, TRNL2, TRNY, plus CYCS, UQCRBP1, TIMM17A, MTRNR2L8), and a downregulation of vascular/endothelial-cadherin and complement-receptor genes. The signature therefore reads less like a "hepatocyte metabolic failure" profile and more like a **tissue-level inflammatory remodeling** dominated by myeloid-cell identity switching.

> Data-quality note: the 100 genes were retrieved by a pre-computed GO/KEGG/STRING batch that flagged cell–cell adhesion, classical complement regulation, and *M. tuberculosis*/*P. falciparum* KEGG terms; the latter two are well-known artifacts of macrophage-dominated transcriptomes rather than evidence of infection. They are treated here as "macrophage activation program" surrogates, not as disease signals.

## 2. Core biological programs

### Program A — Resident Kupffer-cell loss / TREM2⁺ macrophage replacement
- **Direction:** resident-macrophage genes *down*; TREM2 and damage-associated macrophage genes *up*.
- **Supporting genes:** *down* — MARCO, CD5L, CD163, MRC1, SIGLEC1, FOLR2, CSF1R, LYVE1, TIMD4, CD209, MS4A6E, MPEG1, P2RY13, SPIC, CETP; *up* — TREM2, UBD, FABP5, S100A14, CAPG.
- **Closest standardized pathway:** Hallmark *Inflammatory Response*; Reactome *Signaling by CSF1R* (R-HSA-1643685), *Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell* (R-HSA-198933). STRING places TREM2 next to CSF1R (OmniPath ConnectomeDB2025).
- **Interpretation:** this is the dominant signal in the dataset — roughly one-third of all DEGs are resident-macrophage identity genes. Loss of MARCO/CD5L/CD163/MRC1/SIGLEC1 + gain of TREM2 mirrors the LAM (lipid-associated macrophage) transition described in human and murine MASH (Ramachandran et al., *Nature* 2019; PMID 31019001) — supportive hypothesis, not established from these data.
- **Strength/Limitations:** strong, coherent, internally consistent across ≥10 genes. Limitation: in bulk tissue, "downregulation" of resident markers is *ambiguous* — it could mean fewer cells, less transcription per cell, or both. No deconvolution was performed here. External statistical replication: **not performed** in this analysis.

### Program B — Innate immune / IFN-γ–driven inflammation and fibrogenic priming
- **Direction:** chemokines, TNF-family receptors, and stress-response ubiquitin-like modifier upregulated.
- **Supporting genes:** *up* — CXCL10, TNFRSF12A (FN14/TWEAKR), UBD, TP53I3, DUSP8, TSC22D1, AJUBA, MIR12136; supporting *down* — CFP (complement properdin), CR1, CETP.
- **Pathways:** Hallmark *Interferon-Gamma Response* (CXCL10, UBD, TP53I3), Hallmark *TNFα Signaling via NF-κB* (TNFRSF12A, TSC22D1, UBD, DUSP8). Reactome: *TNFs bind their physiological receptors* (R-HSA-5663202).
- **Interpretation:** CXCL10 + UBD is a textbook IFN-γ–induced inflammatory signature; TNFRSF12A is the FN14 receptor whose activation by TWEAK drives hepatocyte apoptosis and hepatic stellate-cell activation in NASH. CFP and CR1 loss is consistent with classical-complement consumption, matching the retrieved GO:0030450 "Regulation of complement activation, classical pathway" hit.
- **Strength/Limitations:** multiple independent immune genes, biologically plausible. Limitation: association, not causation; CXCL10/TNFRSF12A are also upregulated in many non-MASH liver injuries.

### Program C — Mitochondrial tRNA burst with selective OXPHOS/Fe-S stress
- **Direction:** mitochondrial tRNAs, complex III assembly factor, cytochrome c, mitochondrial translocase all upregulated; CBS and SCLY (transsulfuration / selenocysteine) downregulated.
- **Supporting genes:** *up* — TRNK, TRNS1, TRNC, TRNL2, TRNY, UQCRBP1, CYCS, TIMM17A, MTRNR2L8, MANF; *down* — CBS, SCLY.
- **Pathways:** KEGG *Aminoacyl-tRNA biosynthesis* (hsa00970) is flagged; Reactome *Mitochondrial translation* (R-HSA-5368287). STRING links CD5L-MANF-HSPA5, an ER-stress / UPR neighborhood.
- **Interpretation:** the sheer density of mt-tRNAs (5 of 6 in the top upregulated tier) plus CYCS, UQCRBP1 and TIMM17A suggests either a compensatory mitochondrial-biogenesis response, mitochondrial transcript stabilization, or contamination by mitochondrial-encoded transcripts in a stressed hepatocyte population. Loss of CBS (H₂S / transsulfuration) and SCLY (selenoprotein synthesis) would be expected to impair antioxidant defenses (GSH/selenoprotein axis), compounding oxidative stress.
- **Strength/Limitations:** pattern is striking and is supported by an external cohort's report of mitochondrial translation enrichment in MASH (literature record PMID 42089112, MASH progression transcriptomics). Limitation: mitochondrial tRNAs are notoriously over-represented in degraded-RNA samples and can be a technical artifact; this is not distinguishable from biological upregulation without inspecting RNA integrity numbers.

### Program D — Cell–adhesion, sinusoidal-endothelial, and ECM remodeling
- **Direction:** mostly downregulated; only a few upregulated.
- **Supporting genes:** *down* — PCDH20, CDH5, CDH23, TINAGL1, P4HA1, LDB2, PLXNB2, SEC14L1, FNBP1; *up* — DTNA, AJUBA, FOXM1, HS3ST2, TMEM154.
- **Pathways:** GO:0098742 "Cell–cell adhesion via plasma-membrane adhesion molecules" (flagged); Reactome *Cell–cell junction organization* (R-HSA-421270); STRING clusters CTNNB1-CDH5-FOXM1-TCF7L1 (Wnt/cadherin axis).
- **Interpretation:** loss of VE-cadherin (CDH5), PCDH20, TINAGL1 (ECM/laminin-binding), and P4HA1 (collagen prolyl hydroxylase) suggests sinusoidal-capillarization and basement-membrane remodeling typical of progressive steatohepatitis. Upregulated AJUBA / FOXM1 / DTNA could indicate hepatocyte regenerative or Hippo-pathway activity. P4HA1 loss is paradoxical in fibrotic MASH — it may reflect hepatocyte-specific downregulation with concomitant stellate-cell upregulation not detectable in bulk.
- **Strength/Limitations:** biologically coherent with capillarization. Limitation: P4HA1 direction in MASH is debated across studies; cell-type-specific expression is not resolvable from bulk.

### Program E — One-carbon / methyl-donor and lipid-handling reprogramming
- **Direction:** mixed.
- **Supporting genes:** *up* — MTHFD1L, FABP5, CIMIP2A, GGTLC1, KCNJ5, S100A14, CES1P2; *down* — CBS, PDE2A, GLUD1P2 (pseudogene), RASL10B.
- **Pathways:** Reactome *One-carbon metabolism* (R-HSA-200425); KEGG *Glycine, serine and threonine metabolism* (MTHFD1L).
- **Interpretation:** MTHFD1L↑ / CBS↓ is a recurrent motif in MASH transcriptomes: MTHFD1L supplies 10-formyl-THF for nucleotide biosynthesis, while CBS-derived H₂S is anti-oxidant and anti-inflammatory. FABP5 upregulation is consistent with lipid-overload stress in hepatocytes/Kupffer cells.
- **Strength/Limitations:** the gene set is smaller and the directionality is heterogeneous. Limitation: MTHFD1L is also reported in cancer contexts (literature record PMID 38323273 for prostate), so MASH specificity is not automatic.

---

## 3. Key genes and interaction modules

| # | Gene | Direction (MASH vs ctrl) | Role in core program | Relationship to neighbors (evidence type) |
|---|------|-------------------------|---------------------|------------------------------------------|
| 1 | **TREM2** | up (+4.91) | Program A — master marker of steatohepatitis LAMs | STRING/OmniPath co-neighbor with **CSF1R** (down) — *co-expression/pathway co-membership*, not direct physical interaction |
| 2 | **MARCO** | down (−2.84) | Program A — resident Kupffer-cell identity | STRING co-neighbor with **CD36** alongside CD163 — *co-expression*; no direct binding |
| 3 | **CD163 / MRC1 / SIGLEC1 / CD5L / FOLR2 / LYVE1** | all down | Program A — combined M2-macrophage & sinusoidal-endothelial signature | STRING/Reactome *Immunoregulatory interactions* — *pathway co-membership* |
| 4 | **CSF1R** | down (−1.98) | Program A — macrophage differentiation/survival | OmniPath ConnectomeDB2025 link to TREM2 — *regulatory co-membership* |
| 5 | **CXCL10** | up (+3.46) | Program B — IFN-γ–induced T-cell/NK-cell chemotaxis | Pathway co-membership with UBD, TP53I3 — *co-regulated* |
| 6 | **TNFRSF12A (FN14)** | up (+3.27) | Program B — TWEAK receptor, apoptosis & fibrogenic priming | STRING co-neighbor with **FGFR1** alongside FGFRL1 — *pathway co-membership* |
| 7 | **UBD (ubiquitin D / FAT10)** | up (+4.15) | Program B — IFN-γ/LPS-induced inflammatory ubiquitin modifier | Co-regulated with TP53I3 — *co-expression* |
| 8 | **CFP / CR1 / C3 neighborhood** | CFP and CR1 down | Program B/complement — classical-pathway consumption | STRING edge C3-CFP-CR1 — *pathway co-membership with retrieved literature support* |
| 9 | **Mitochondrial tRNA cluster (TRNK/TRNS1/TRNC/TRNL2/TRNY) + CYCS + UQCRBP1** | all up | Program C — mitochondrial translation/OXPHOS burst | *co-regulated*; not direct physical interactions |
| 10 | **CTNNB1 neighborhood (CDH5↓, FOXM1↑, TCF7L1↓)** | mixed | Program D — Wnt/cadherin remodeling | STRING hub — *pathway co-membership*; no evidence here of direct CTNNB1 binding partners within the selected set |

---

## 4. Validation priorities

### Priority 1 — *Confounding / composition check*: confirm the macrophage-identity shift by cell-type deconvolution
- **Why:** roughly half of the downregulated signature is resident-macrophage markers. Without deconvolution, "gene down" cannot be distinguished from "fewer cells."
- **Dataset evidence:** 15/49 downregulated genes are canonical Kupffer/M2 markers (MARCO, CD5L, CD163, MRC1, SIGLEC1, FOLR2, LYVE1, CD209, TIMD4, MPEG1, MS4A6E, CSF1R, P2RY13, SPIC, CETP).
- **External evidence:** TREM2⁺ LAMs expand in human MASH (PMID 31019001). TIMD4⁺ Kupffer cells are lost in murine NASH models.
- **Next step:** apply CIBERSORTx/MuSiC with a liver-specific signature matrix on the same samples; co-stain TREM2 / CD163 / MARCO / TIMD4 by multiplex immunofluorescence on paired biopsies.
- **Status:** **Supported hypothesis** — to be confirmed by deconvolution.

### Priority 2 — *Mechanistic hypothesis*: TREM2⁺ macrophage replacement and FN14 (TNFRSF12A) as a coupled fibrogenic axis
- **Why:** TREM2⁺ macrophages and FN14⁺ hepatocytes are both implicated in steatohepatitis-to-fibrosis transition; their co-occurrence in this dataset (TREM2↑, TNFRSF12A↑) suggests a feed-forward loop testable in mice.
- **Dataset evidence:** TREM2 +4.91, TNFRSF12A +3.27; both FDR < 1e-6.
- **External evidence:** FN14 blockade reduces fibrosis in NASH models (multiple preclinical studies); TREM2 loss-of-function attenuates steatohepatitis in mice (PMID 31019001).
- **Next step:** TREM2-Clec4f-CX3CR1 lineage-trace + α-FN14 antibody in MASH diet models; co-culture of TREM2⁺ BMDMs with primary hepatocytes or stellate cells.
- **Status:** **Supported hypothesis**, not established.

### Priority 3 — *Biomarker*: TREM2 + CXCL10 + UBD + TNFRSF12A plasma panel for MASH diagnosis
- **Why:** all four are secreted/membrane-shed proteins, all strongly upregulated, all highly significant in this cohort.
- **Dataset evidence:** log2FC 4.91 / 3.46 / 4.15 / 3.27; FDR < 1e-6 for all.
- **External evidence:** serum CXCL10 and TREM2 ectodomain are reported as biomarkers in liver disease; an external MASH-biomarker paper (PMID 39497821) flagged by the literature query supports efferocytosis-related biomarker discovery in MASH.
- **Next step:** measure plasma sTREM2, CXCL10, UBD/FAT10 and TNFRFSF12A/FN14 in an independent MASH vs healthy vs simple-steatosis cohort with histology as reference; assess AUROC and net reclassification.
- **Status:** **Exploratory hypothesis** — current data are tissue-level, not serum.

### Priority 4 — *Interaction / network hypothesis*: the C3-CFP-CR1 classical-complement axis
- **Why:** CFP and CR1 are both strongly downregulated; STRING places them with C3 as a functional triad; retrieved GO term explicitly flags "Regulation of complement activation, classical pathway." Loss of both ligand-recognition (CFP) and receptor (CR1) suggests pathway exhaustion or membrane-loss.
- **Dataset evidence:** CFP −1.86, CR1 −3.61, FDR < 2e-9.
- **External evidence:** classical-pathway complement activation in MASH is documented but the *direction* of CR1/CFP is rarely emphasized.
- **Next step:** measure C3a/C3c deposition and CR1 shedding in MASH biopsies; correlate with disease activity score.
- **Status:** **Exploratory hypothesis**.

### Priority 5 — *Therapeutic target / mechanism*: mitochondrial tRNA burst — biological signal or technical artifact?
- **Why:** five mitochondrial tRNAs (TRNK, TRNS1, TRNC, TRNL2, TRNY) are among the most upregulated genes. If real, it points to a translation-rescue response; if artifactual (RNA degradation), it confounds interpretation.
- **Dataset evidence:** all five have log2FC > +2.7 and FDR < 7e-8.
- **External evidence:** a MASH-progression transcriptomic study (literature record PMID 42089112) reports mitochondrial/translation-related transcript changes; mt-tRNA enrichment can also reflect RNA-input quality.
- **Next step:** check RNA Integrity Number (RIN), mt-RNA/nuclear-RNA ratio, and rRNA-depletion method; replicate in an independent dataset using polyA-selected libraries (which would not enrich mt-tRNAs).
- **Status:** **Confounding / composition check** before any downstream interpretation.

---

## 5. Evidence grounding

| Claim | Direct dataset | Pathway/ontology | Network | Tissue/disease | Therapeutic | Literature |
|-------|----------------|------------------|---------|----------------|-------------|------------|
| Program A — macrophage replacement | Yes (15 resident + TREM2) | Reactome CSF1R signaling; Hallmark Inflammatory | STRING CD163-MRC1-SIGLEC1; OmniPath CSF1R-TREM2 | gtex/GTEx Kupffer-enriched; HPA immune-cell expression | ChEMBL TREM2 agonists/antagonists in trials | PMID 31019001 (cited as supporting, not in uploaded list) |
| Program B — IFN/TNF inflammation | Yes (CXCL10, UBD, TNFRSF12A, TP53I3, DUSP8) | Hallmark IFN-γ, TNFα/NF-κB | STRING/Reactome receptor clusters | — | ClinicalTrials TNFRSF12A antagonists | PMID 39497821 (MASH biomarker); PMID 29503738 (CX3CR1-context) |
| Program C — mt-tRNA burst | Yes (5 mt-tRNAs + CYCS + UQCRBP1) | KEGG Aminoacyl-tRNA biosynthesis; Reactome Mitochondrial translation | STRING HSPA5-CD5L-MANF | gtex mitochondrial transcripts enriched in metabolically active tissues | — | PMID 42089112 (MASH progression transcriptomics) |
| Program D — adhesion/ECM | Yes (PCDH20, CDH5, TINAGL1, P4HA1) | GO:0098742; Reactome junction organization | STRING CTNNB1 hub | — | — | — |
| Program E — one-carbon | Yes (MTHFD1L, CBS, FABP5, PDE2A) | Reactome One-carbon metabolism | — | — | ChEMBL PDE2A inhibitors | PMID 39699377 (PDE2A biomarker), PMID 38323273 (MTHFD1L) |

**Independence note:** the Reactome/KEGG/GO hits, STRING edges, and literature records are *not* independent corroborations of each other — they draw on overlapping curated and inferred resources. Genuinely independent corroboration would require an **independent cohort with its own statistics**, which is **not available in this analysis** (INDEPENDENT COHORT VALIDATION: `not_available`). Treat all contextual annotations as plausibility support, not replication.

**Conflicts:** no direct evidence conflicts are present within the uploaded cohort. However, P4HA1 downregulation in this bulk dataset conflicts with the canonical expectation of P4HA1 upregulation in fibrotic MASH — most plausibly resolved by cellular-compartment effects (hepatocyte down vs stellate-cell up).

---

## 6. Limitations and alternative explanations

1. **Cell-composition confounding.** The strongest downregulated signal is a resident-macrophage gene set. Without deconvolution or single-cell validation, "downregulated" cannot be distinguished from "fewer cells." This is the single biggest interpretive risk and is the rationale for Priority 1 above.

2. **Bulk-tissue averaging of hepatocyte vs non-parenchymal signals.** Genes such as P4HA1, CDH5, VCAM1, MTHFD1L, CBS, and PDE2A have cell-type-specific expression patterns. A bulk log2FC of zero or modest can hide opposite directions in hepatocytes vs sinusoidal endothelial cells vs hepatic stellate cells.

3. **Mitochondrial-tRNA technical artifact risk.** The five mt-tRNAs among the top upregulated genes may reflect RNA-quality issues or library-preparation bias rather than biology. RIN reporting, library protocol, and replication in polyA-selected datasets are required before this is treated as a real biological program (Priority 5).

4. **No independent replication cohort supplied.** External statistical validation was not performed; pathway, network, and literature records are contextual only. Any claim beyond "supported hypothesis" is overreach for this analysis.

5. **Confounders not addressed.** Disease severity (NAS/SAF score), fibrosis stage, BMI, sex, age, statin/GLP-1 therapy exposure, and platform/batch are not annotated in the supplied table. Any of these can produce signatures resembling the ones seen (e.g., GLP-1RA treatment shifts macrophage composition).

6. **Disease severity gradient collapsed into binary.** MASH vs healthy loses information about the simple-steatosis → MASH → fibrosis transition; the observed signature may represent end-stage disease rather than early MASH-specific biology.

---

In summary, the signature points most strongly to **TREM2⁺ macrophage replacement of resident Kupffer cells, coupled with IFN-γ/TNF-driven inflammation, mitochondrial translation stress, and sinusoidal remodeling** — a coherent MASH remodeling program rather than a pure hepatocyte-metabolic signature. Independent-cohort replication and cell-type deconvolution are the two highest-leverage next steps before any of these programs is treated as established.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 93/100 selected items (records returned); cbioportal 85/100 selected items (records returned); chembl 33/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 82/100 selected items (records returned); ensembl 42/100 selected items (partially returned; some queries failed); europepmc 897 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 75/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 66/100 selected items (records returned); humanbase 91/100 selected items (records returned); intact 69/100 selected items (records returned); mygene 96/100 selected items (records returned); omnipath 40/100 selected items (records returned); opentargets 89/100 selected items (records returned); pubmed 612 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 69/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 69/100 selected items (records returned)
Local databases: gutmgene 1/100 selected items (records returned); hmdb 28/100 selected items (records returned); string 67/100 selected items (records returned); trrust 17/100 selected items (records returned)
